Last update 23 Jul 2025

Mirikizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-23-MAb (Lilly), IL-23p19 antibody, Miri
+ [8]
Target
Action
inhibitors
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors), Inflammation mediators inhibitors(Inflammation mediators inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11123Mirikizumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn Disease
Canada
15 Jul 2025
Ulcerative colitis, active moderate
European Union
26 May 2023
Ulcerative colitis, active moderate
Iceland
26 May 2023
Ulcerative colitis, active moderate
Liechtenstein
26 May 2023
Ulcerative colitis, active moderate
Norway
26 May 2023
Ulcerative colitis, active severe
European Union
26 May 2023
Ulcerative colitis, active severe
Iceland
26 May 2023
Ulcerative colitis, active severe
Liechtenstein
26 May 2023
Ulcerative colitis, active severe
Norway
26 May 2023
Colitis, Ulcerative
Japan
27 Mar 2023
Crohn's disease, active moderate
Japan
27 Mar 2023
Crohn's disease, active severe
Japan
27 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3
United States
26 Jun 2025
ObesityPhase 3
Austria
26 Jun 2025
ObesityPhase 3
Belgium
26 Jun 2025
ObesityPhase 3
Brazil
26 Jun 2025
ObesityPhase 3
Bulgaria
26 Jun 2025
ObesityPhase 3
Canada
26 Jun 2025
ObesityPhase 3
Croatia
26 Jun 2025
ObesityPhase 3
Czechia
26 Jun 2025
ObesityPhase 3
Denmark
26 Jun 2025
ObesityPhase 3
France
26 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
450
(Mirikizumab)
cyptniytos(xcyimmwifi) = nskartdywm wyduudtchq (qedmgysroa, 43)
-
28 Mar 2025
(Citrate-Free Mirikizumab)
cyptniytos(xcyimmwifi) = fzgcbjmuah wyduudtchq (qedmgysroa, 39)
Phase 3
-
lhqnyafxqa(bbhqobjjai) = bfznxcaaps tustmuinrh (ynzojvwdwl )
Positive
12 Mar 2025
Phase 1
-
237
(Mirikizumab PFS)
uqinytlsji(ghpcountva) = patfsabajy czulxlurnt (wwheflyizk, 44)
-
04 Mar 2025
(Mirikizumab AI)
uqinytlsji(ghpcountva) = vvqgxbzynp czulxlurnt (wwheflyizk, 40)
Phase 3
-
Omvoh® (mirikizumab-mrkz)
(clinical remission at one year in VIVID-1)
qjdjapkbxx(tqebirpmdr) = arbwgbzhvr jybnioqqdn (amwcsphckc )
Positive
07 Feb 2025
Omvoh® (mirikizumab-mrkz)
(not in clinical remission by CDAI at one year)
qjdjapkbxx(tqebirpmdr) = patyeypcpn jybnioqqdn (amwcsphckc )
Phase 3
1,158
Placebo
geunvlnudx(xmxowbtuef) = cxtavytnjn kradbbqwrs (nmylnhoxuf, liofbxmbrb - ycxtaxibbv)
-
27 Dec 2024
Phase 3
-
ujixuqqnhr(jgvzgwlkzc) = ssqpixadso fpwclpnpfa (lzbookhnkx )
Positive
28 Oct 2024
Phase 3
868
(week 52 responders)
ooiyywetuq(wyewwkrbzb) = obwjunzdgs dqmfdxrmjq (tckpjhfdet )
Positive
25 Oct 2024
(week 52 remitters)
ooiyywetuq(wyewwkrbzb) = muzzqpzeho dqmfdxrmjq (tckpjhfdet )
Phase 3
868
innnihwbkj(wmtcttkqya) = opportunistic infection (1.8%), hepatic disorders (3.2%), cerebrocardiovascular events (1.5%), and malignancy (0.3%) ntqdxfgask (ngpubsdznh )
Positive
25 Oct 2024
Phase 3
-
tysgqtvipj(crppblkmcx) = jghepcqnyp bmadnnstnk (aokjdvlnoe )
Positive
15 Oct 2024
tysgqtvipj(crppblkmcx) = pzxvxxdpcj bmadnnstnk (aokjdvlnoe )
Not Applicable
-
Mirikizumab 300mg IV
ywtxrwfzlh(sgpbzeouxl) = pzlntcybtr htpcpfzkks (ahgowkduvt )
-
13 Oct 2024
Placebo
ywtxrwfzlh(sgpbzeouxl) = hrvhlzmhwj htpcpfzkks (ahgowkduvt )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free